According to JPMorgan, Elanco Animal Health is worth buying the opportunity even after this year’s rally. Analyst Chris Schott upgraded Elanco from neutral to overweight on Tuesday, saying American pharmaceutical companies have many attractive products for pets and livestock. “We are upgrading Elan stock from N to an attractive innovation cycle,” writes Schott. “The launch of Credelio Quattro is much more advanced than expected as products begin to gain traction in some of the market and become meaningful contributors to revenue. Experience (along with a wider farm animal portfolio) is also working well. “While Credelio Quattro, Experience and other recent launches (such as Zenrelia Exus, Bovaer, IL-31), we can see that revenue growth is accelerating in Elan over the next few years (expected to pass P&L support margins and EPS),” he continued. The Credelio Quattro is a potentially chewable tablet for dogs that offers extensive parasite protection. Experiencer is a beef feed supplement that reduces ammonia gas emissions. Elan 1D Mountain Elanco Animal Health, One Day Performance Elanco shares outperformed in 2025, surged by 70% in the year when the S&P 500 advanced more than 14%. It has defeated the performance of many high-tech companies in MegaCap. However, analysts said Elanco remains attractive at the rally. The $24 price target, previously hiked from $18, represents an upside of animal health stock of more than 16% since Monday’s closing price. Stocks were more than 3% higher on the market on Tuesday. “Elan stocks have run strong this year, but as the company continues to run, we see a favorable setup from here (and the estimates are likely to increase over time),” writes Schott. (Learn the best 2026 strategies from within NYSE with Josh Brown and others on CNBC Pro Live. Tickets and info here.)
